PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media289772ArticlesСтатьиResearch ArticleEW INITIATIVES AND RECOMMENDATIONS OF THE WORLD HEALTH ORGANIZATION FOR THE PREVENTION AND TREATMENT OF SEXUALLY TRANSMITTED DISEASESНОВЫЕ ИНИЦИАТИВЫ И РЕКОМЕНДАЦИИ ВСЕМИРНОЙ ОРГАНИЗАЦИИ ЗДРАВООХРАНЕНИЯ ПО ПРОФИЛАКТИКЕ И ЛЕЧЕНИЮ ИНФЕКЦИЙ, ПЕРЕДАВАЕМЫХ ПОЛОВЫМ ПУТЕМDikkeG. BДиккеГ. Б

Honored Worker of Science and Education, MD, Professor at the Department of Obstetrics, Gynecology and Reproductive Medicine of the Faculty of Advanced Training of Medical Practitioners

заслуженный деятель науки и образования, д.м.н., проф. кафедры акушерства, гинекологии и репродуктивной медицины факультета повышения квалификации медицинских работников

galadikke@yandex.ruFSAEI HE «Peoples' Friendship University of Russia»ФГАОУ ВО «Российский университет дружбы народов»10022017243NO3 (2017)№3 (2017)61126022023Copyright ©; 2017, Bionika MediaCopyright ©; 2017, ООО «Бионика Медиа»2017Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/289772

The article presents the main directions of prevention and treatment of sexually transmitted diseases (STDs) in the current conditions of increasing antibiotic resistance of microorganisms. Materials of WHO, Cochrane Community, and recommendations of leading professional societies were used. Established facts on resistance to antimicrobial agents among causative microorganisms of STDs, factors accelerating the emergence and spread of antibiotic resistance; recommendations on treatment, and main directions of STDs control according to WHO recommendation at current stage are discussed. It is emphasized that therapeutic and preventive use of antibiotics in an era of ever-increasing antimicrobial resistance should be strictly justified. Any arbitrary decisions unsupported by evidence-based data, both in terms of unjustified administration, and, on the contrary, refusal of the use of antibiotics when indicated, should be excluded.

Представлены основные направления профилактики и лечения инфекций, передаваемых половым путем (ИППП), в современных условиях повышения резистентности микроорганизмов к антибиотикам. Использованы материалы ВОЗ, Кокрейновского сообщества, рекомендации ведущих профессиональных сообществ. Приведены установленные факты о резистентности микроорганизмов среди ИППП к антимикробным препаратам; факторы, ускоряющие появление и распространение устойчивости к ним; рекомендации по лечению; основные направления борьбы с ИППП, предложенные ВОЗ на современном этапе. Подчеркивается, что применение антибиотиков в эпоху всевозрастающей резистентности микроорганизмов к ним как с лечебной, так и с профилактической целью должно быть строго обосновано. Любые произвольные решения, не подкрепленные доказательными данными, как в отношении необоснованного назначения, так и, наоборот, отказа от применения антибиотиков при наличии показаний должны быть исключены.

sexually transmitted diseasesmicroorganismsresistanceantibioticsинфекциипередаваемые половым путеммикроорганизмырезистентностьантибиотикиWHO. Antimicrobial resistance: global report on surveillance. 2014. 257p. http://www.who.int/Report on global sexually transmitted infection surveillance 2015. World Health Organization 2016. 62 р. http://www.who.int/Newman L., Rowley J., Vander Hoorn S., Wijesooriya N.S., Unemo M., Low N., et al. Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting. Published: December 8, 2015.WHO. Surveillance of Antimicrobial Resistance for Local and Global Action. Stockholm on 2-3 December 2014. http://www.who.int/WHO guidelines for the Treatment of Chlamydia trachomatis. 2016. 47 р.WHO guidelines for the Treatment of Neisseria gonorrhoeae. 2016. 55 р.Lau C.Y., Qureshi A.K. Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials. Sex Transm. Dis. 2002;29:497-502.Jensen J.S., Cusini M., Gomberg M., Moi H. European guideline on Mycoplasma genitalium infections (2016). 6 European Academy of Dermatology and Venereology. JEADV. 2016. 7 p. http://www.iusti.org/Savaris R.F., Teixeira L.M., Torres T.G., Edelweiss M.I., Moncada J., Schachter J. Comparing ceftriaxone plus azithromycin or doxicicline for pelvic inflammatory disease: a randomized controlled trial. Obctr. Gynecol. 2007;110(1):53-60.Диагностика и лечение заболеваний, сопровождающихся патологическими выделениями из половых путей женщин. РОАГ Коллектив авторов. М., 2013. 50 с.Workowski K.A., Bolan G. Sexually Transmitted Diseases Treatment Guidelines. CDC, 2014. http:// www.cdc.gov/Swidsinski A., Mendling W., Loening-Baucke V., Swidsinski S., Dörffel Y., Scholze J., Lochs H., Verstraelen H. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am. J. Obstet. Gynecol. 2008;198(1):97.e1-61.Swidsinski A., Verstraelen H., Loening-Baucke V., Swidsinski S., Mendling W., Halwani Z. Presence of a polymicrobial endometrial biofilm in patients with bacterial vaginosis. PLoS One. 2013;8(1):e53997.McMillan А., Dell M., Zellar M.P., Cribby S., Martz S., Hong E., Fu J., Abbas A., Dang T., Miller W., Reid G. Disruption of urogenital biofilms by lactobacilli. Colloids Surf. B Biointerfaces. 2011;86:58-64.Oduyebo O.O., Anorlu R.I., Ogunsola F.T. The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women. Cochrane Database Syst Rev. 2009;(3):CD006055.Miller L., Thomas K., Hughes J.P., Holmes K.K., Stout S., Eschenbach D.A. Randomised treatment trial of bacterial vaginosis to prevent post-abortion complication. BJOG. 2004;111(9):982-88.Koumans E.H., Markowitz L.E., Hogan V. CDC BV Working Group. Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data. Clin. Infect. Dis. 2002;35(Suppl 2):S152-72.Макаров И.О., Гомберг М.А., Боровкова Е.И., Аракелян Л.А., Березовская Е.С. Бактериальный вагиноз: состояние изученности проблемы. Акушерство, гинекология и репродукция. 2013;7(4):20-4.Gottschick C., Szafranski S.P., Kunze B., Sztajer H., Masur C., Abels C., Wagner-Döbler I. Screening of Compounds against Gardnerella vaginalis Biofilms. PLoS One. 2016;11(4):e0154086.Menard J.-P. Antibacterial treatment of bacterial vaginosis: current and emerging therapies. Int. J. Womens Health. 2011;3:295-305.Anukam K., Osazuwa E., Ahonkhai I., Ngwu M., Osemene G., Bruce A.W., Reid G. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microbes Infect. 2006;8:1450-54.Mania-Pramanik J., Kerkar S.C., Salvi V.S. Bacterial vaginosis: A cause of infertility? Int. J. STD AIDS. 2009;20:778-81.Beigi R.H., Austin M.N., Meyn L.A., Krohn M.A., Hillier S.L. Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am. J. Obstet. Gynec. 2004;191:1123-29.Burton J.P., Devillard E., Cadieux P.A., Hammond J.A., Reid G. Detection of Atopobium vaginae in postmenopausal women by cultivationindependent methods warrants further investigation. J. Clin. Microbiol. 2004; 42:1829-31.Sherrard J., Donders G., White D., Jensen J.S. European (IUSTI/WHO) Guideline on the Management of Vaginal Discharge. 2011. 23 р. http://www.iusti.org/Yudin M.H., Landers D.V., Meyn L.A., Hillier S.L. Clinical and cervical cytokine response to treatment with oral or vaginal metronidazole for bacterial vaginosis during pregnancy: a randomized trial. Obstet. Gynecol. 2003;102(3):527-34.Truter I., Graz M. Bacterial vaginosis: Literature review of treatment options with specific emphasis on non-antibiotic treatment. Afr. J. Pharm. Pharmacol. 2013;7(48):3060-67.